ArticleBMC infectious diseases2021
Symptomatic SARS-COV-2 reinfection: healthcare workers and immunosuppressed individuals at high risk.
Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global prevalence of coronavirus disease 2019 reinfection: a systematic review and meta-analysis.BMC public health · 2023Pooled it
- Preinfection with Mycoplasma pneumoniae exacerbates subsequent influenza infection in young adults: a retrospective cohort study.BMC infectious diseases · 2025Article
- Article
- Risk of Testing Positive for COVID-19 among Healthcare and Healthcare-Related Workers.Vaccines · 2023Article
- Article
- Evaluation of the Factors Associated with Reinfections towards SARS-CoV-2 Using a Case Control Design.Journal of clinical medicine · 2023Article
- Predictors of Recurrent Laboratory-Confirmed Symptomatic SARS-CoV-2 Infections in a Cohort of Healthcare Workers.Vaccines · 2023Article
- Who Is at Higher Risk of SARS-CoV-2 Reinfection? Results from a Northern Region of Italy.Vaccines · 2022Article
- Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN study.The Journal of infection · 2022Article
- Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada.JAMA network open · 2022Article
- SARS-CoV-2 reinfections in a US university setting, Fall 2020 to Spring 2021.BMC infectious diseases · 2022Article
- SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity.Environmental research · 2022Review
- Confirmed reinfection with SARS-CoV-2 during a pregnancy: A case report.Clinical case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKnowledge regarding factors predicting the SARS-COV-2 reinfection risk is scarce and it has major implications in public health policies. We aimed to identify factors associated with the risk of symptomatic SARS-COV-2 reinfection.
methodsWe conducted a nationwide retrospective cohort study and 99,993 confirmed cases of COVID-19 were analyzed.
resultsThe overall risk of reinfection (28 or more elapsed days between both episodes onset) was 0.21% (incidence density, 2.5 reinfections per 100,000 person-days) and older subjects and those with the mild primary disease were at reduced risk of the event. Healthcare workers and immunosuppressed or renal patients had at greater risk of SARS-COV-2 reinfection.
conclusionsIf replicated in other populations, these results may be useful to prioritize efforts focusing on the reduction of SARS-COV-2 spread and the related burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.